Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Medical Genetics · PIGT-related multiple congenital anomalies-hypotonia-seizures syndrome type 3

The Biology of PIGT: A Story of Hooks and Tethers

At a Glance

PIGT-related MCAHS3 occurs when changes in PIGT disrupt GPI anchors, the molecular tethers that keep important proteins on cell surfaces. This can affect the brain, bones, and eyes and cause low alkaline phosphatase that resembles, but is not the same as, classic hypophosphatasia.

To understand PIGT-related MCAHS3, it helps to look at the microscopic world of your child’s cells. Every cell in the human body is like a busy city. For this city to function, it needs thousands of different proteins to sit on the “sidewalks” (the cell surface) and perform specific jobs, like sending signals to the brain or helping bones harden.

In a healthy cell, these proteins are held in place by a molecular “tether” called a GPI anchor [1][2]. If the tether is missing, the protein cannot stay where it belongs, and it cannot do its job.

The “Tether” Factory and the PIGT Gene

Your child’s cells have a specialized machine—called the GPI-transamidase complex—that acts like a factory worker responsible for transferring these already-assembled tethers to proteins [3][4]. The PIGT gene provides the instructions for one of the most critical parts of this machine.

Think of the PIGT protein as a subunit that helps the machine function:

  • The Job: It is part of the complex that recognizes the tether and stabilizes the entire machine so the “hook” can be transferred onto the protein [5][6].
  • The Defect: In PIGT-related MCAHS3, the subunit is broken or weak. Because the machine cannot reliably attach the tethers, many important proteins never make it to the cell surface, leading to reduced or abnormal cell-surface expression of GPI-anchored proteins [1][2].

Because these tethers are used by hundreds of different proteins throughout the body—in the brain, the eyes, and the skeleton—a single genetic change in PIGT causes a “domino effect” that impacts multiple systems at once [7][8].

The Confusion Over “Hypophosphatasia”

One of the most confusing parts of this diagnosis is a condition called hypophosphatasia (low ALP). Alkaline phosphatase (ALP) is a protein that requires a GPI anchor to sit on the surface of bone cells and help them mineralize [9].

In children with PIGT variations, doctors often find low levels of ALP in the blood [10]. This happens because the “tether” is broken, so the ALP protein cannot attach to the cell surface. This creates a hypophosphatasia-like phenotype because the problem isn’t that the body doesn’t know how to make ALP, but rather that it doesn’t have the “hooks” to hold it in place [10][2].

This is biologically different from classic ALPL-related hypophosphatasia (HPP):

  • Classic HPP: The body has a mutation in the ALPL gene itself. The ALP “tool” is broken [11]. A metabolic specialist may use tests for PLP (Vitamin B6) or phosphoethanolamine to distinguish ALPL-related HPP from other causes of low ALP.
  • PIGT-related Low ALP: The issue is the tethering system, not the ALPL gene itself [9][12].

Important: Low ALP has multiple possible causes and should be interpreted using the laboratory’s pediatric reference range. PIGT-related low ALP should not automatically be treated as classic HPP, and any ALP-related treatment decisions require confirmation by a metabolic bone/genetics specialist. Additionally, ALP levels can sometimes be normal or high in PIGT.

Decoding the Long Names

You may see this condition referred to by several long, intimidating names. They all describe the same biological “tether” problem caused by the PIGT gene:

Name What It Means
PIGT-CDG PIGT-related Congenital Disorder of Glycosylation. This is the scientific category for “tether” defects [2].
MCAHS3 Multiple Congenital Anomalies-Hypotonia-Seizures Syndrome, type 3. This describes the main symptoms [2][13].
Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome This is a “descriptive name” used by some clinical databases to list every major symptom found in some early patients (brain, seizures, low ALP, eyes, and bones) [2][8].

While these names are complex, they all point back to the same source: a struggle to attach the molecular hooks that keep your child’s proteins working where they are needed most.

Why Does It Affect So Many Parts of the Body?

The reason this condition is a “multi-system” disorder is that GPI-anchored proteins are essential for:

  1. Brain Signaling: Helping neurons communicate and keeping the brain’s electrical activity stable (which is why seizures occur) [7][14].
  2. Bone Strength: Anchoring the enzymes that turn soft cartilage into hard bone [15].
  3. Vision: Holding proteins in the retina and front of the eye that are necessary for sight [8].

Because the PIGT gene is active in almost every tissue, the effects of a “broken tether” are felt throughout the entire body [2].

Common questions in this guide

What does the PIGT gene do in MCAHS3?
The PIGT gene provides instructions for a part of the GPI-transamidase complex, the cellular machinery that attaches GPI anchors to certain proteins. When PIGT is altered, some of these proteins may not reach or remain on cell surfaces where they are needed.
Why can PIGT-related MCAHS3 cause low alkaline phosphatase?
Alkaline phosphatase, or ALP, normally uses a GPI anchor to stay on the surface of bone cells and help mineralization. If the anchoring system is impaired, blood ALP may be low even though the ALPL gene itself is not the problem.
Is low ALP from PIGT the same as classic hypophosphatasia?
No. Classic hypophosphatasia is caused by changes in ALPL, whereas PIGT-related low ALP results from a problem attaching the GPI anchor. Because ALP can have multiple causes and may sometimes be normal or high in PIGT-related disease, results should be interpreted using age-specific pediatric ranges by a metabolic bone or genetics specialist.
What do PIGT-CDG and MCAHS3 mean?
PIGT-CDG refers to PIGT-related congenital disorder of glycosylation, a scientific category for the tethering defect. MCAHS3 describes the combination of congenital anomalies, low muscle tone, and seizures; both names refer to the same PIGT-related condition described on this page.
Can a test show whether GPI anchors are missing?
Flow cytometry on white blood cells can be used to examine the amount of GPI-anchored proteins on the cell surface. A clinician may use this result, along with genetic and clinical information, to understand how the PIGT change affects the tethering system.
Why does PIGT-related MCAHS3 affect the brain, bones, and eyes?
GPI-anchored proteins help neurons communicate, support bone mineralization, and maintain proteins needed for vision. Because PIGT is active in many tissues, impaired anchoring can affect several body systems at once.
Which specialists may help interpret PIGT-related low ALP?
A medical genetics team and a metabolic bone specialist can help distinguish PIGT-related low ALP from classic hypophosphatasia and interpret age-specific results. A biochemist or another relevant specialist may also be involved in evaluating how the tethering defect affects the child's bones and eyes.

Get notified when new evidence is published on Intellectual disability-seizures-hypophosphatasia-ophthalmic-skeletal anomalies syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    Novel PIGT Variant in Two Brothers: Expansion of the Multiple Congenital Anomalies-Hypotonia Seizures Syndrome 3 Phenotype.

    Skauli N, Wallace S, Chiang SC, et al.

    Genes 2016; (7(12)).

    PMID: 27916860
  2. 2

    Expanding the clinical and molecular characteristics of PIGT-CDG, a disorder of glycosylphosphatidylinositol anchors.

    Lam C, Golas GA, Davids M, et al.

    Molecular genetics and metabolism 2015; (115(2-3)):128-140 doi:10.1016/j.ymgme.2015.04.007.

    PMID: 25943031
  3. 3

    Structure and Function of the Glycosylphosphatidylinositol Transamidase, a Transmembrane Complex Catalyzing GPI Anchoring of Proteins.

    Li D

    Sub-cellular biochemistry 2024; (104()):425-458 doi:10.1007/978-3-031-58843-3_16.

    PMID: 38963495
  4. 4

    Stability of the transamidase complex catalyzing GPI anchoring of proteins.

    Kawaguchi K, Sato T, Kondo S, et al.

    Biochemical and biophysical research communications 2019; (512(3)):584-590 doi:10.1016/j.bbrc.2019.03.103.

    PMID: 30914202
  5. 5

    Structure of human glycosylphosphatidylinositol transamidase.

    Zhang H, Su J, Li B, et al.

    Nature structural & molecular biology 2022; (29(3)):203-209 doi:10.1038/s41594-022-00726-6.

    PMID: 35165458
  6. 6

    Functional Analysis of the GPI Transamidase Complex by Screening for Amino Acid Mutations in Each Subunit.

    Liu SS, Jin F, Liu YS, et al.

    Molecules (Basel, Switzerland) 2021; (26(18)) doi:10.3390/molecules26185462.

    PMID: 34576938
  7. 7

    PIGT-CDG, a disorder of the glycosylphosphatidylinositol anchor: description of 13 novel patients and expansion of the clinical characteristics.

    Bayat A, Knaus A, Juul AW, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(10)):2216-2223 doi:10.1038/s41436-019-0512-3.

    PMID: 30976099
  8. 8

    Bilateral anterior segment dysgenesis and peripheral avascular retina with tractional retinal detachment in an infant with multiple congenital anomalies-hypotony-seizures syndrome 3.

    Wu F, Goldenberg PC, Mukai S

    Ophthalmic genetics 2021; (42(3)):334-337 doi:10.1080/13816810.2021.1888133.

    PMID: 33620284
  9. 9

    Effects of GPI-anchored TNAP on the dynamic structure of model membranes.

    Garcia AF, Simão AM, Bolean M, et al.

    Physical chemistry chemical physics : PCCP 2015; (17(39)):26295-301 doi:10.1039/c5cp02377g.

    PMID: 26389140
  10. 10

    Epileptic apnea in a patient with inherited glycosylphosphatidylinositol anchor deficiency and PIGT mutations.

    Kohashi K, Ishiyama A, Yuasa S, et al.

    Brain & development 2018; (40(1)):53-57 doi:10.1016/j.braindev.2017.06.005.

    PMID: 28728837
  11. 11

    Vitamin B6 deficiency with normal plasma levels of pyridoxal 5'-phosphate in perinatal hypophosphatasia.

    Whyte MP, May JD, McAlister WH, et al.

    Bone 2021; (150()):116007 doi:10.1016/j.bone.2021.116007.

    PMID: 34000433
  12. 12

    Expanding the Phenotypic Spectrum of GPI Anchoring Deficiency Due to Biallelic Variants in GPAA1.

    Castle AMR, Salian S, Bassan H, et al.

    Neurology. Genetics 2021; (7(6)):e631 doi:10.1212/NXG.0000000000000631.

    PMID: 34703884
  13. 13

    A PIGN mutation responsible for multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1) in an Israeli-Arab family.

    Khayat M, Tilghman JM, Chervinsky I, et al.

    American journal of medical genetics. Part A 2016; (170A(1)):176-82 doi:10.1002/ajmg.a.37375.

    PMID: 26364997
  14. 14

    Disorders affecting vitamin B6 metabolism.

    Wilson MP, Plecko B, Mills PB, Clayton PT

    Journal of inherited metabolic disease 2019; (42(4)):629-646 doi:10.1002/jimd.12060.

    PMID: 30671974
  15. 15

    [Hypophosphatasia: Clinical manifestations, diagnostic recommendations and therapeutic options].

    Martos-Moreno GA, Calzada J, Couce ML, Argente J

    Anales de pediatria 2018; (88(6)):356.e1-356.e11 doi:10.1016/j.anpedi.2017.06.004.

    PMID: 28720214

This page explains the biology of PIGT-related MCAHS3 and the difference between PIGT-related low ALP and classic hypophosphatasia for informational purposes only; it does not constitute medical advice. A metabolic bone or genetics specialist should interpret your child's results and guide any treatment decisions.